See a complete PubMed list of publications by Ekihiro Seki, MD, PhD.

Select Key Publications

Song IJ, Yang YM, Inokuchi-Shimizu S, Roh YS, Yang L, Seki E. The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice. Int J Cancer. 2018 Jan 1;142(1):81-91.

Yang L, Miura K, Zhang B, Matsushita H, Yang YM, Liang S, Song J, Roh YS, Seki E. TRIF differentially regulates hepatic steatosis and inflammation/fibrosis in mice. Cell Mol Gastroenterol Hepatol. 2017 Jan 17;3(3):469-483.

Roh YS, Zhang B, Loomba R, Seki E. TLR2 and TLR9 contribute to alcohol-mediated liver injury through induction of CXCL1 and neutrophil infiltration. Am J Physiol Gastrointest Liver Physiol. 2015 Jul 1;309(1):G30-41.

Zhang B, Roh YS, Liang S, Liu C, Naiki M, Masuda K, Seki E. Neurotropin suppresses inflammatory cytokine expression and cell death through suppression of NF-κB and JNK in hepatocytes. PLOS One. 2014 Dec 3;9(12):e114071.

Inokuchi-Shimizu S, Park EJ, Yang L, Roh YS, Zhang B, Song J, Pimienta M, Taniguchi K, Wu X, Lagakos WS, Mackey MR, Akira S, Ellisman MH, Sears DD, Olefsky JM, Karin M, Brenner DA, Seki E. TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis. J Clin Invest. 2014;124(8):3566-3578.

Liu C, Chen X, Yang L, Kisseleva T, Brenner DA, Seki E. Transcriptional repression of the transforming growth factor β (TGF-β) pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI) by nuclear factor κB (NF-κB) p50 enhances TGF-β signaling in hepatic stellate cells. J Biol Chem. 2014;289(10):7082-7091.

Yang L, Roh YS, Song J, Zhang B, Liu C, Loomba R, Seki E. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology 2014;59(2):483-495.

Yang L, Inokuchi S, Roh YS, Song J, Loomba R, Park EJ, Seki E. Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. Gastroenterology2013;144(5):1042-1054.e4.

Miura K, Ohnishi H, van Rooijen N, Ohnishi H, Seki E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol. 2012;302 (11): G1310-1321.

Inokuchi S, Tsukamoto H, Park EJ, Liu Z-X, Brenner DA, Seki E. Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. Alcohol Clin Exp Res. 2011;35(8):1509-1158.

Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Olefsky JM, Brenner DA, Seki E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology 2010;139(1):323-334.e7.   

Inokuchi S, Aoyama T, Miura K, Österreicher CH, Kodama Y, Miyai K, Akira S, Brenner DA, Seki E. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis and carcinogenesis. Proc Natl Acad Sci U S A. 2010:107(2):844-849.

Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, Llovet JM, Brenner DA, Schwabe RF. CCR1 and CCR5 promote hepatic fibrosis. J Clin Invest. 2009;119(7):1858-1870.

Seki E, De Minicis, S, Inokuchi S, Taura K, Miyai K, van Rooijen N, Schwabe RF, Brenner DA. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009; 50(1):185-197.;jsessionid=340E4F0AF9D13AC582FAF20A343C76C8.f04t03

Seki E, De Minicis S, Österreicher, CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGFβ signaling and hepatic fibrosis. Nature Medicine 2007;13:1324-1332.